on HBM Healthcare Investments AG (ETR:CH001262)
HBM Healthcare Completes Swixx Biopharma Transaction
HBM Healthcare Investments AG has successfully closed a transaction involving the sale of a majority equity stake in Swixx Biopharma. SK Capital Partners and Bain Capital Life Sciences are the new majority owners. Despite this sale, HBM Healthcare will retain an approximate 8% ownership in Swixx Biopharma.
Swixx Biopharma, established in 2014, has become a prominent platform for biopharmaceutical commercialization, thanks to robust organic growth and geographical expansion. The company is poised for further growth with the support of its new stakeholders.
HBM Healthcare, which first invested in Swixx Biopharma in 2017, has seen significant returns from this partnership, marking it as the firm’s top-performing investment.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HBM Healthcare Investments AG news